CELU

Celularity Inc.

Celularity Inc., a clinical-stage biotechnology company, develops off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer, immune, and infectious diseases. It operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. The company's lead therapeutic programs include CYCART-19, a placental-derived CAR-T therapy, which is in Phase I clinical trial for the treatment of B-cell malignancies; CYNK-001, placental-derived unmodified natural killer (NK) cell that is in Phase I clinical trial to treat acute myeloid leukemia, as well as in Phase I/IIa clinical trial for the treatment of glioblastoma multiforme and COVID-19; CYNK-101, an allogeneic genetically modified NK cell, which is in Phase I clinical trial to treat HER2+ gastric and gastroesophageal cancers; APPL-001, a placenta-derived mesenchymal-like adherent stromal cell that is in a pre-clinical stage for the treatment of Crohn's disease; and PDA-002, a placenta-derived mesenchymal-like adherent stromal cell, which is in pre-clinical stage for the treatment of facioscapulohumeral muscular dystrophy. It also sells and licenses products that are used in surgical and wound care markets, such as Biovance and Interfyl; collects stem cells from umbilical cords and placentas; and provides cells storage under the LifebankUSA brand. The company was incorporated in 2016 and is headquartered in Florham Park, New Jersey.

Celularity Inc. (CELU) is rated C+ (2.8/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Momentum (B+); its weakest is Growth (D+). The rating has held at C+ for 2 weeks.

Quantitative Factor Evaluation • Updated

Overall Rating
2.8 / 5.0
C+
Value
B-
Factor Score 3.0 / 5.0
Growth
D+
Factor Score 1.8 / 5.0
Profitability
C+
Factor Score 2.6 / 5.0
Momentum
B+
Factor Score 3.8 / 5.0
Revisions
C+
Factor Score 2.6 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio -1.2
EV / EBITDA -2.2
Rev Growth YoY -5.3%
Gross Margin 19.2%
Price Return 3M 3.0%
Price Return 12M -60.1%
Catalyst Signal 0.00
Market Cap $23.1M
TTM Revenue $18.7M
Price / Sales 1.2
ROE N/A

Historical Factor Score Progression

Held C+ for 2 weeks
Date Value Growth Profitability Momentum Revisions Overall
2026-11-11 B- (3.0) D+ (1.8) C+ (2.6) B+ (3.8) C+ (2.6) C+ (2.8)
2026-11-04 B- (3.0) D+ (1.8) C+ (2.6) A- (3.9) C+ (2.7) C+ (2.8)
2026-10-28 B- (3.0) D+ (1.8) C+ (2.7) B (3.4) C+ (2.7) C+ (2.7)
2026-10-21 B- (3.0) F (0.4) C (2.4) B- (3.0) C+ (2.6) C (2.3)
2026-10-14 B- (3.0) F (0.4) C (2.4) B- (3.1) C+ (2.6) C (2.3)
Page 1 of 4